MRSA: Methicillin-resistant Staphylococcus aureus; MSSA: Methicillin-sensitive Staphylococcus aureus

PHARMACOKINETICS 

Orally administered faropenem medoxomil is readily absorbed. The addition of the medoxomil ester to the faropenem moiety improves bioavailability. The bioavailability of faropenem medoxomil is proposed to be 70–80%, which is approximately four times that of faropenem sodium.11https://m.chemicalbook.com/Article/Pharmacokinetics-of-Faropenem.htm [accessed May 18 2023] The half-life of faropenem medoxomil is estimated to be 0.9 hours. Administration of faropenem medoxomil under fasting and postprandial conditions resulted in no significant difference in Cmax and AUC.

Clinical Evidence for Faropenem